title: The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for acute mania.
abstract: This new algorithm for the pharmacotherapy of acute mania was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. The authors conducted a literature search in PubMed and reviewed key studies, other algorithms and guidelines, and their references. Treatments were prioritized considering three main considerations: (1) effectiveness in treating the current episode, (2) preventing potential relapses to depression, and (3) minimizing side effects over the short and long term. The algorithm presupposes that clinicians have made an accurate diagnosis, decided how to manage contributing medical causes (including substance misuse), discontinued antidepressants, and considered the patient's childbearing potential. We propose different algorithms for mixed and nonmixed mania. Patients with mixed mania may be treated first with a second-generation antipsychotic, of which the first choice is quetiapine because of its greater efficacy for depressive symptoms and episodes in bipolar disorder. Valproate and then either lithium or carbamazepine may be added. For nonmixed mania, lithium is the first-line recommendation. A second-generation antipsychotic can be added. Again, quetiapine is favored, but if quetiapine is unacceptable, risperidone is the next choice. Olanzapine is not considered a first-line treatment due to its long-term side effects, but it could be second-line. If the patient, whether mixed or nonmixed, is still refractory to the above medications, then depending on what has already been tried, consider carbamazepine, haloperidol, olanzapine, risperidone, and valproate first tier; aripiprazole, asenapine, and ziprasidone second tier; and clozapine third tier (because of its weaker evidence base and greater side effects). Electroconvulsive therapy may be considered at any point in the algorithm if the patient has a history of positive response or is intolerant of medications.
authors.affiliation: From Harvard Medical School; Boston Children's Hospital, Boston, MA (Dr. Mohammad); VA Boston Healthcare System, Brockton Division, Brockton, MA (Dr. Osser).
authors.forename: Othman
authors.initials: O
authors.lastname: Mohammad
authors.forename: David N
authors.initials: DN
authors.lastname: Osser
mesh_terms: D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001714:Bipolar Disorder / Q000188:drug therapy*; D002985:Clinical Protocols / Q000592:standards*; D006801:Humans; D011600:Psychopharmacology / Q000592:standards*
chemical_list: D014150:Antipsychotic Agents